Premetastatic soil and prevention of breast cancer brain metastasis

Neuro-Oncology

Volumn 15, Issue 7, 2013, Pages 891-903

  Liu, Yan ^a,b   Kosaka, Akemi ^a,b   Ikeura, Maki ^a   Kohanbash, Gary ^a,c   Fellows Mayle, Wendy ^b   Snyder, Linda A ^d   Okada, Hideho ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

brain metastasis; breast cancer; CCL2; myeloid derived suppressor cells; prostaglandin E2; S100A8 A9

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CALGRANULIN A; CALGRANULIN B; CD11B ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; MESSENGER RNA; POLYCLONAL ANTIBODY; PROSTAGLANDIN E2; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BRAIN METASTASIS; BRAIN TISSUE; BREAST ADENOCARCINOMA; BREAST CANCER; CELL INFILTRATION; CONTROLLED STUDY; GENE SILENCING; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; TUMOR CELL;

BRAIN METASTASIS; BREAST CANCER; CCL2; MYELOID-DERIVED SUPPRESSOR CELLS; PROSTAGLANDIN-E2; S100A8/A9;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD11B; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CALGRANULIN B; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; LEUKOCYTES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; MYELOID CELLS; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84879372754     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not031     Document Type: Article

References (52)

1. Palmieri D, Smith QR, Lockman PR, et al. Brain metastases of breast cancer. Breast Dis. 2006; 26: 139-147. (Pubitemid 46647419)
2. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005; 167(4): 913-920. (Pubitemid 41416243)
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004; 22(17): 3608-3617. (Pubitemid 41103668)
4. Martin JJ, Kondziolka D. Indications for resection and radiosurgery for brain metastases. Curr Opin Oncol. 2005; 17(6): 584-587. (Pubitemid 41566412)
5. Kondziolka D, Kano H, Harrison GL, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. J Neurosurg. 2011; 114(3): 792-800.
6. Kaplan R, Psaila B, LydenD. Bonemarrowcells in the 'pre-metastatic niche': within bone and beyond. Cancer Metast Rev. 2006; 25(4): 521-529. (Pubitemid 46071861)
7. Maru Y. Logical structures extracted from metastasis experiments. Cancer Sci. 2009; 100(11): 2006-2013.
8. Hiratsuka S, Watanabe A, Sakurai Y, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008; 10(11): 1349-1355.
9. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 Breast Tumor Model. Current Protocols in Immunology. New York: John Wiley & Sons, Inc. 2001.
10. Fujita M, Zhu X, Ueda R, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells - significant roles of CXCL10. Cancer Res. 2009; 69(4): 1587-1595.
11. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011; 71(7): 2664-2674.
12. Fujita M, Scheurer ME, Decker SA, et al. Role of type 1 IFNs in antiglioma immunosurveillance-using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010; 16(13): 3409-3419.
13. Liu Y, Komohara Y, Domenick N, et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012; 61(6): 789-801.
14. Olkhanud PB, Baatar D, Bodogai M, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009; 69(14): 5996-6004.
15. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 2011; 475(7355): 226-230.
16. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011; 71(24): 7463-7470.
17. Pyonteck SM, Gadea BB, Wang HW, et al. Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene. 2012; 31(11): 1459-1467.
18. Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J Immunol. 1995; 154(9): 4309-4321.
19. Eue I, König S, Pior J, Sorg C. S100A8, S100A9 and the S100A8/A9 heterodimer complex specifically bind to human endothelial cells: identification and characterization of ligands for the myeloid-related proteins S100A9 and S100A8/A9 on human dermal microvascular endothelial cell line-1 cells. Internat Immunol. 2002; 14(3): 287-297. (Pubitemid 34213640)
20. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003; 60(6): 569-580.
21. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007; 13(9): 1042-1049. (Pubitemid 47517513)
22. Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29(10): 2035-2043.
23. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 2011; 9(2): 133-148.
24. Srikrishna G, Turovskaya O, Shaikh R, et al. Carboxylated glycans mediate colitis through activation of NF-kB. J Immunol. 2005; 175(8): 5412-5422. (Pubitemid 41456427)
25. Ristima? ki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62(3): 632-635. (Pubitemid 34126931)
26. Capone PM, Kadohama N, Chu TM. Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody. Cancer Immunol Immunother. 1987; 25(2): 93-99. (Pubitemid 18028851)
27. Chao TY, Chu TM. Characterization of a new spontaneously developed murine mammary adenocarcinoma in syngeneic BALB/c hosts. In vitro Cell Dev Biol. 1989; 25(7): 621-626.
28. Divino CM, Chen SH, Yang W, Thung S, Brower ST, Woo SL. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res Treat. 2000; 60(2): 129-134. (Pubitemid 30307472)
29. Zhu X, Fujita M, Snyder L, Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for gliomatherapy. JNeuro-Onc. 2011; 104(1): 83-92.
30. Qian B-Z, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475(7355): 222-225.
31. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998; 58(7): 1486-1493. (Pubitemid 28193612)
32. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67(9): 4507-4513. (Pubitemid 46815102)
33. Gil-Bernabé AM, FerjančičS, Tlalka M, et al. Recruitment of monocytes/ macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012; 119(13): 3164-3175.
34. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006; 8(12): 1369-1375. (Pubitemid 44835111)
35. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4): 253-268.
36. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010; 59(10): 1593-1600.
37. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992; 257(5069): 548-551.
38. Fleming T, Fleming M, Malek T. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993; 151(5): 2399-2408. (Pubitemid 23264492)
39. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008; 181(7): 4666-4675.
40. Manitz M-P, Horst B, Seeliger S, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol. 2003; 23(3): 1034-1043. (Pubitemid 36133519)
41. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011; 7(9): 528-536.
42. Pickup J, Mattock M, Chusney G, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40(11): 1286-1292. (Pubitemid 27469668)
43. Han CY, Subramanian S, Chan CK, et al. Adipocyte-derived serum amyloid A3 and gyaluronan play a role in monocyte recruitment and adhesion. Diabetes. 2007; 56(9): 2260-2273. (Pubitemid 47358233)
44. Tomita T, Sakurai Y, Ishibashi S, Maru Y. Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis. Oncogene. 2011; 30(31): 3429-3439.
45. Son D-S, Roby KF, Terranova PF. Tumor necrosis factor-a induces serum amyloid A3 in mouse granulosa cells. Endocrinology. 2004; 145(5): 2245-2252. (Pubitemid 38535053)
46. Xu K, Geczy CL. IFN-g and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J Immunol. 2000; 164(9): 4916-4923. (Pubitemid 30238097)
47. Lucci A, Krishnamurthy S, Singh B, et al. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009; 117(1): 61-68.
48. Huang B, Lei Z, Zhao J, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007; 252(1): 86-92. (Pubitemid 46734559)
49. Fridlender ZG, Buchlis G, Kapoor V, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010; 70(1): 109-118.
50. Sinha P, Clements V, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother. 2005; 54(11): 1137-1142. (Pubitemid 41396817)
51. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379(9826): 1591-1601.
52. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010; 10(3): 181-193.